Comparative Pharmacology
Head-to-head clinical analysis: PHOSLO versus PHOSLO GELCAPS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PHOSLO versus PHOSLO GELCAPS.
PHOSLO vs PHOSLO GELCAPS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Calcium acetate binds phosphate in the gastrointestinal tract, forming insoluble calcium phosphate that is excreted in feces, thereby reducing serum phosphate levels.
Calcium acetate binds dietary phosphate in the gastrointestinal tract, forming insoluble calcium phosphate complexes that are excreted in feces, thereby reducing serum phosphate levels.
667 mg (two 667-mg tablets or one 667-mg capsule) orally three times daily with meals, titrated to maintain serum phosphate between 3.5-5.5 mg/dL; maximum 4000 mg/day.
Oral: One to two capsules (668-1336 mg calcium acetate) three times daily with meals, titrated to maintain serum phosphate between 3.5-5.5 mg/dL, maximum 4 capsules per meal.
None Documented
None Documented
Not applicable; minimal systemic absorption, local gastrointestinal action
Not applicable; calcium is a physiologic ion with dynamic regulation; steady-state serum calcium is maintained by homeostatic mechanisms. In overdose, serum calcium half-life is approximately 3-4 hours.
Primarily fecal as unabsorbed drug; minimal renal elimination (<0.5%)
Primarily fecal as unabsorbed calcium; renal excretion accounts for <1% of absorbed dose proportional to glomerular filtration rate.
Category C
Category C
Phosphate Binder
Phosphate Binder